On May 27, 2025 TCG Labs Soleil, a venture firm integrating dedicated capital with an in-house biotech R&D hub, and EpimAb Biotherapeutics, Inc. ("EpimAb") reported that Juri Biosciences, Inc. ("Juri"), a portfolio company of TCG Labs Soleil, has entered into a worldwide licensing agreement with EpimAb, a clinical-stage biopharmaceutical company specializing in the discovery and development of multi-specific antibodies for diseases with high unmet need (Press release, EpimAb Biotherapeutics, MAY 27, 2025, View Source [SID1234654051]). The agreement grants Juri exclusive global rights to a development-ready T-cell engager targeting kallikrein-related peptidase 2 (KLK2) and CD3 for the treatment of metastatic prostate cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, EpimAb is eligible to receive up to $210 million, including an upfront payment and milestone payments tied to development, regulatory, and commercial events, plus tiered royalties. Further financial details were not disclosed.
Juri is one of several portfolio companies formed by TCG Labs Soleil. Dr. Charles Sawyersi, the inaugural Director of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, will serve as a strategic scientific advisor, working closely with the TCG Labs Soleil team to support the program and help guide the advancement of KLK2-directed therapies. A leading expert in metastatic prostate cancer and translational oncology, Dr. Sawyers co-discovered enzalutamide, one of the most widely used therapies for advanced prostate cancer today.
"This agreement with EpimAb is a clear demonstration of our venture-biotech model at work. We’ve acquired an exciting external innovation and are deploying our dedicated capital, scientific leadership and operational infrastructure to move it rapidly into the clinic," said Jin-Long Chen, Ph.D., Managing Partner of TCG Labs and Chief Executive Officer of TCG Labs Soleil. "Prostate cancer remains a leading cause of cancer-related death in men, and KLK2 is a highly prostate-specific antigen with the potential to enable more precise, targeted therapy. We look forward to advancing this program through our portfolio company, Juri Biosciences."
Chengbin Wu, Ph.D., Founder and Chief Executive Officer of EpimAb Biotherapeutics, commented, "We are pleased to have identified a partner for our KLK2 program in Juri Biosciences, backed by the experienced team of TCG Labs Soleil. By partnering in the solid tumor space, EpimAb further validated the broad potential of our TCE platform beyond immunology and hematology."